MedPath

efficacy and safety of allergen extract dropping therapy for severe peanut and nut (walnut) allergy

Not Applicable
Recruiting
Conditions
food allergy
Registration Number
JPRN-UMIN000048007
Lead Sponsor
Yokohama Nishikage Clinic: kids and allergies
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

the subjects who have the conditions bellow 1.poorly controlled atopic dermatitis 2.poorly controlled asthma 3.immunodeficiency 4.taking beta blockers 5. pregnancy 6. taking medications for psychiatric disorders except child developmental disorders 7.malignant diseases

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the rate of the subjects who could have been administered a usual oral immunotherapy using peanut or nut(walnut) powder in mg unit during the test period.
Secondary Outcome Measures
NameTimeMethod
1.oral challenge threshold changes of serially diluted allergen extracts; verified every month till 24 months after the research start. 2. oral challenge threshold changes of antigen powders in mg units.(every month) 3.threshold changes of skin prick tests of serially diluted allergen extracts.(every year) 4. changes of wheel size of skin prick tests of diluted allergen extracts.( every year) 5. antigen specific IgE level change (every year) 6.Basophil Activation Test results on several diluted allergen extracts(before and after the study) 7.the rate of subjects who could intake allergen nut containing foods. 8.safety evaluation (the rate of adverse reactions at challenge phases in a clinic setting and maintenance phases at home)
© Copyright 2025. All Rights Reserved by MedPath